Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Indaptus Therapeutics (Nasdaq: INDP), a clinical stage biotechnology company, announced a $2.25 million private placement priced at-the-market under Nasdaq rules. The placement involves the issuance and sale of 2,109,383 shares of common stock and accompanying warrants to purchase an equal number of shares. Each share and warrant combination is priced at $1.065. The closing is expected around January 15, 2025, subject to customary closing conditions. The warrants, exercisable immediately at $0.94 per share, have a five-year term. Paulson Investment Company, is the exclusive placement agent for this offering. The gross proceeds are anticipated to be around $2.25 million, before deducting placement agent fees and other expenses. Indaptus plans to use the net proceeds to fund research and development, working capital, and general corporate purposes. The securities are offered under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D, not registered under the Securities Act or state securities laws, and cannot be resold in the U.S. without registration or an applicable exemption.
Indaptus Therapeutics (Nasdaq: INDP), una società biotecnologica in fase clinica, ha annunciato un collocamento privato di 2,25 milioni di dollari effettuato secondo le regole di Nasdaq. Il collocamento prevede l'emissione e la vendita di 2.109.383 azioni ordinarie e relativi warrant per acquistare un numero uguale di azioni. Ogni combinazione di azione e warrant è valutata 1,065 dollari. La chiusura è prevista intorno al 15 gennaio 2025, soggetta a condizioni di chiusura consuete. I warrant, esercitabili immediatamente a 0,94 dollari per azione, hanno una durata di cinque anni. Paulson Investment Company è l'agente di collocamento esclusivo per questa offerta. Si prevede che gli incassi lordi siano attorno ai 2,25 milioni di dollari, prima della deduzione delle spese per l'agente di collocamento e altre spese. Indaptus intende utilizzare il netto per finanziare la ricerca e lo sviluppo, il capitale circolante e scopi aziendali generali. I titoli sono offerti ai sensi della Sezione 4(a)(2) del Securities Act del 1933 e della Regola 506(b) del Regolamento D, non registrati ai sensi del Securities Act o delle leggi statali sui valori mobiliari, e non possono essere rivenduti negli Stati Uniti senza registrazione o un'esenzione applicabile.
Indaptus Therapeutics (Nasdaq: INDP), una empresa biofarmacéutica en etapa clínica, anunció un colocación privada de 2,25 millones de dólares a precio de mercado según las reglas de Nasdaq. La colocación implica la emisión y venta de 2.109.383 acciones ordinarias y warrants acompañantes para comprar un número igual de acciones. Cada combinación de acción y warrant está valorada en 1,065 dólares. Se espera que el cierre ocurra alrededor del 15 de enero de 2025, sujeto a condiciones de cierre habituales. Los warrants, ejercitables inmediatamente a 0,94 dólares por acción, tienen un plazo de cinco años. Paulson Investment Company es el agente exclusivo de colocación para esta oferta. Se anticipa que los ingresos brutos sean de alrededor de 2,25 millones de dólares, antes de deducir las tarifas del agente de colocación y otros gastos. Indaptus planea utilizar los fondos netos para financiar investigación y desarrollo, capital de trabajo y propósitos corporativos generales. Los valores se ofrecen bajo la Sección 4(a)(2) de la Ley de Valores de 1933 y la Regla 506(b) del Reglamento D, no están registrados bajo la Ley de Valores o las leyes estatales de valores, y no pueden ser revendidos en EE. UU. sin registro o una exención aplicable.
Indaptus Therapeutics (Nasdaq: INDP)는 임상 단계의 생명공학 회사로, 225만 달러 규모의 사모펀드를 나스닥 규정에 따라 시장가로 발표했습니다. 이 사모펀드는 2,109,383주의 보통주와 동수의 주식을 구매할 수 있는 워런트의 발행 및 판매를 포함합니다. 각 주식 및 워런트 조합의 가격은 1.065달러입니다. 마감은 2025년 1월 15일경에 예상되며, 일반적인 마감 조건이 적용됩니다. 파울슨 투자회사는 이번 제안의 독점적인 배급 에이전트입니다. 총 수익은 225만 달러가 될 것으로 예상되며, 배급 에이전트 수수료 및 기타 경비 공제 전 금액입니다. Indaptus는 순자금을 연구 개발, 운영 자본 및 일반 기업 목적에 사용하려고 합니다. 이 증권은 1933년 증권법 섹션 4(a)(2) 및 규정 D의 506(b) 규정에 따라 제공되며, 증권법 또는 주 증권법에 따라 등록되지 않으며, 등록 또는 적용 가능한 면제 없이 미국에서 재판매할 수 없습니다.
Indaptus Therapeutics (Nasdaq: INDP), une entreprise de biotechnologie en phase clinique, a annoncé un placement privé de 2,25 millions de dollars effectué à prix de marché selon les règles de Nasdaq. Le placement implique l'émission et la vente de 2 109 383 actions ordinaires ainsi que de warrants correspondants permettant d'acheter le même nombre d'actions. Chaque combinaison d'action et de warrant est évaluée à 1,065 dollar. La clôture est prévue autour du 15 janvier 2025, sous réserve de conditions de clôture habituelles. Les warrants, exerçables immédiatement à 0,94 dollar par action, ont une durée de cinq ans. Paulson Investment Company est l'agent de placement exclusif pour cette offre. Les produits bruts devraient atteindre environ 2,25 millions de dollars, avant déduction des frais d'agent de placement et d'autres dépenses. Indaptus prévoit d'utiliser le produit net pour financer la recherche et le développement, le fonds de roulement et les fins générales d'entreprise. Les valeurs mobilières sont offertes en vertu de la Section 4(a)(2) de la Loi sur les valeurs mobilières de 1933 et de la règle 506(b) du Règlement D, non enregistrées en vertu de la Loi sur les valeurs mobilières ou des lois étatiques sur les valeurs mobilières, et ne peuvent pas être revendues aux États-Unis sans enregistrement ou exemption applicable.
Indaptus Therapeutics (Nasdaq: INDP), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat eine private Platzierung von 2,25 Millionen Dollar angekündigt, die zum Marktpreis gemäß den Nasdaq-Regeln erfolgt. Die Platzierung umfasst die Emission und den Verkauf von 2.109.383 Stammaktien sowie begleitenden Warrants zum Erwerb einer gleichen Anzahl von Aktien. Jede Kombination aus Aktie und Warrant ist mit 1,065 Dollar bewertet. Der Abschluss wird um den 15. Januar 2025 herum erwartet und unterliegt den üblichen Abschlussbedingungen. Die Warrants, die sofort zu 0,94 Dollar pro Aktie ausgeübt werden können, haben eine Laufzeit von fünf Jahren. Paulson Investment Company ist der exklusive Platzierungsagent für dieses Angebot. Die brutto Erlöse werden voraussichtlich bei etwa 2,25 Millionen Dollar liegen, bevor die Gebühren des Platzierungsagenten und andere Kosten abgezogen werden. Indaptus plant, die Nettoerlöse für Forschung und Entwicklung, Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Die Wertpapiere werden gemäß Abschnitt 4(a)(2) des Securities Act von 1933 und Regel 506(b) des Regulation D angeboten, sind nicht nach dem Securities Act oder den staatlichen Wertpapiergesetzen registriert und können in den USA ohne Registrierung oder eine anwendbare Ausnahme nicht weiterverkauft werden.
- Indaptus Therapeutics secures $2.25 million in gross proceeds.
- Net proceeds will fund research and development, working capital, and general corporate purposes.
- Shareholder dilution due to issuance of 2,109,383 shares and accompanying warrants.
- Warrants exercisable at $0.94 per share, which could lead to further dilution.
NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors for the issuance and sale in a private placement priced at-the-market under Nasdaq rules of an aggregate of 2,109,383 of its shares of common stock and accompanying warrants to purchase up to an aggregate of 2,109,383 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is
The warrants will have an exercise price of
Paulson Investment Company, LLC is acting as the exclusive placement agent in connection with the offering.
The gross proceeds to Indaptus from the offering are expected to be approximately
The shares of common stock and warrants to be issued in the private placement and shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506(b) of Regulation D promulgated thereunder, have not been registered under the Securities Act or applicable state securities laws and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements regarding the gross proceeds from the private placement and anticipated use of the net proceeds. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Indaptus’ actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to risks related to market conditions. Other important factors discussed under the caption “Risk Factors” included in Indaptus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC on November 12, 2024, its most recent Annual Report on Form 10-K filed with the SEC on March 13, 2024, and its other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. Indaptus undertakes no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:
CORE IR
Louie Toma
louie@coreir.com
FAQ
What is the total amount Indaptus Therapeutics will raise in the private placement?
What is the price per share and warrant combination in the Indaptus Therapeutics private placement?
When is the closing date for the Indaptus Therapeutics private placement?
What is the exercise price for the warrants issued by Indaptus Therapeutics?
How will Indaptus Therapeutics use the proceeds from the private placement?
What is the term of the warrants issued in the Indaptus Therapeutics private placement?
